Apricus Biosciences Inc (NASDAQ:APRI) : Average target price received by Apricus Biosciences Inc (NASDAQ:APRI) is $2.56 with an expected standard deviation of $1.89. The most aggressive target on the stock is $4, whereas the most downbeat target is $1. 3 financial analysts are currently covering the stock.
Other Equity analysts have also commented on the company shares. Taglich Brothers maintains its view on Apricus Biosciences Inc (NASDAQ:APRI) according to the research report released by the firm to its investors. The shares have now been rated Speculative Buy by the stock experts at the ratings house. Taglich Brothers lowers the price target from $4.25 per share to $2.95 per share on Apricus Biosciences Inc. The rating by the firm was issued on March 15, 2016.
Apricus Biosciences Inc (NASDAQ:APRI): On Thursdays trading session , Opening price of the stock was $0.5 with an intraday high of $0.595. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.461. However, the stock managed to close at $0.47, a loss of 1.88% for the day. On the previous day, the stock had closed at $0.479. The total traded volume of the day was 6,320,954 shares.
The company shares have dropped -72.09% from its 1 Year high price. On Sep 10, 2015, the shares registered one year high at $1.99 and the one year low was seen on May 17, 2016. The 50-Day Moving Average price is $0.43 and the 200 Day Moving Average price is recorded at $0.81. On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chief Development Officer) of Apricus Biosciences, Inc., Dorsey Brian, had purchased 10,000 shares in a transaction dated on December 29, 2014. The transaction was executed at $1.05 per share with total amount equaling $10,500.
Apricus Biosciences, Inc. is a pharmaceutical company focused on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The Companys drug delivery technology is a permeation enhancer called NexACT. The Company has one approved drug, Vitaros, which uses the NexACT delivery system, and is approved for the treatment of erectile dysfunction (ED) in Canada and through the European Decentralized Procedure (DCP) in Europe. The Companys other pipeline includes RayVa, Fispemifene and Femprox. RayVa utilizes the Companys permeation enhancer for the treatment of Raynauds phenomenon secondary to scleroderma. Fispemifene a tissue-specific selective estrogen receptor modulator (SERM) used for the treatment of secondary hypogonadism. Femprox is used for the treatment of female sexual interest and arousal disorder (FSIAD). The Company owns or exclusively licenses approximately 331 issued patents and 194 patent applications.